We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
- Authors
Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex
- Abstract
In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research. Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery programme was initiated with the aim of rationally developing targeted anticancer therapies. Here, we describe how this programme led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.
- Publication
Nature reviews. Drug discovery, 2002, Vol 1, Issue 7, p493
- ISSN
1474-1776
- Publication type
Journal Article
- DOI
10.1038/nrd839